Bannerbild German Brest Group - Forschung

Forschungsprojekte und Publikationen der German Breast Group

Die German Breast Group erforscht Brustkrebs und setzt dafür selbst entwickelte Studienkonzepte um.

Mit zusätzlichen wissenschaftlichen Forschungsprojekten wollen wir weitere Erkenntnisse über die Krankheit gewinnen.

Neuste Forschungsnachrichten

  • 31.07.2018 Paper of the month: BRCA1/2 Mutations and Bevacizumab

    A translational research study performed with samples obtained from a cohort of patients with triple-negative breast cancer (TNBC) enrolled in the neoadjuvant GeparQuinto (GBG 44) study has been published in the Journal of Clinical Oncology.

  • 06.07.2018 Review on Endocrine Therapy in Premenopausal HR+/HER2- Metastatic Breast Cancer

    Unser Review zur Endokrine Therapie in prämenopausale Patientinnen mit Hormone Rezeptor-positivem, HER2-negativem metastasiertem Brust Krebs wurde in The Oncologist publiziert.

  • 30.06.2018 Paper of the month: test predicts the risk of recurrence in luminal breast cancer

    A translational study including samples from two randomized neoadjuvant GBG trials (GeparTrio and GeparQuattro) that aimed to evaluate a novel test (mEPclin) for predicting the risk of distance recurrence after neoadjuvant chemotherapy in patients with residual estrogen receptor (ER)-positive/HER2-negative breast cancer has been published in the Clinical Cancer Research.

  • 04.06.2018 ASCO: GeparNuevo Presentation

    GeparNuevo Results of primary objective were presented at ASCO 2018: Durvalumab increases the pCR rate in TNBC patients.

  • 31.05.2018 Paper of the month: elderly women and neoadjuvant chemotherapy

    A pooled analysis using data from eight GBG trials (GeparDuo, GeparTrio pilot and main, GeparQuattro, AGO-1, PREPARE, TECHNO; GeparQuinto) that aimed to help selecting appropriately the elderly women who would benefit from neoadjuvant chemotherapy has been published in the Oncotarget.

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd